wollt:
Trinity Biotech Announces 2004 Results
February 22, 2005 09:21:00 AM ET
Revenues Increase 22%
DUBLIN, Ireland, February 22 /PRNewswire-FirstCall/ -- Trinity Biotech plc (NASDAQ: TRIB, ISE: TRIB.I) today announced results for the quarter and year ended December 31, 2004.
Annual revenues increased 22% from US$65.68 million in 2003 to US$79.94 million in 2004. Q4 revenues, compared to the same period last year, have increased by 42%. Revenues by key product area were as follows :
2003 2004 %
US$000 US$000 Increase
Infectious Disease (excl 30,678 31,638 3%
rapids)
Coagulation 24,435 26,772 10%
Rapids 4,449 9,807 120%
Other 6,113 11,727 92%
Total 65,675 79,944 22%
Revenues by geographical location were as follows :
2003 2004 %
US$000 US$000 Increase
USA 36,299 41,380 14%
Europe 19,983 22,654 13%
Asia / Africa 9,393 15,910 69%
Total 65,675 79,944 22%
Gross profit in the quarter amounted to US$10.93 million, representing a gross margin of 49.6%. The annual gross margin of 50.4% compares to 49.9% in 2003. SG&A expenses have remained relatively constant quarter on quarter at approximately US$7.4 million. The increase in SG&A costs from US$16.69 million in 2003 to US$27.30 million in the current year is primarily attributable to the increased salesforce in the USA.
The net effect of the above factors was a profit after tax of US$1.75 million for the quarter and an EPS of 3.10 US cents. The annual profit after tax was US$5.17 million and annual EPS was 9.37 US cents.
Commenting on the results, Rory Nealon, Chief Financial Officer, said "2004 was a very good year for Trinity in that we increased our sales by 22% to US$80 million and despite increasing our SG&A costs, primarily in the USA, from US$16.7 million to US$27.3 million (an increase which will pay dividends in the future) we still achieved EBITDA of US$10.1 million and a profit after tax of US$5.2 million. The key objectives for our expanded salesforce in the USA are to grow sales of our Unigold rapid HIV test, to significantly increase our market share in the coagulation market, to recover business from our US distributor and to expand our presence in the infectious disease market. To this end the provision of Adaltis instrumentation provides Trinity for the first time with an instrumentation platform which permits us to offer an integrated reagent and instrumentation package for our infectious disease customers. During the year we have also successfully integrated the Fitzgerald operations into the Trinity group and this is reflected in an increase in our Other Sales from US$6.1 million to US$11.7 million."
Ronan O'Caoimh, CEO commented "The strategic goal of Trinity is to attain revenues of at least US$250 million by 2009. Trinity has developed into a geographically diverse diagnostic company with a broad instrumentation and reagent product range in infectious disease, coagulation and point of care testing. We also have an enviable distribution network with direct sales in the USA, Germany and the UK and a wide distributor network in seventy eight countries. The ongoing growth of our business will continue to be focused on our infectious disease, coagulation and rapid product ranges. We will actively seek earnings accretive acquisitions and will focus on delivering improved returns from our existing business."
Trinity Biotech develops, acquires, manufactures and markets over 500 diagnostic products for the point-of-care and clinical laboratory segments of the diagnostic market. The broad line of test kits are used to detect infectious diseases, sexually transmitted diseases, blood coagulation disorders, and autoimmune diseases. Trinity Biotech sells worldwide in 78 countries through its own salesforce and a network of international distributors and strategic partners. For further information please see the Company's website: www.trinitybiotech.com
so sieht es bei der konkurrenz aus! ich habe euch doch gesagt, ihr kommt zu spät, selbst fü den fal, dass caly was auf die beine stellen sollte.
wann kommt bei den hardlinern die einsicht?
|
1 |
... |
167 |
168 |
|
170 |
171 |
...
| 203
Thread abonnieren
